[go: up one dir, main page]

TWI847445B - 一種噠嗪類化合物、其藥物組合物及應用 - Google Patents

一種噠嗪類化合物、其藥物組合物及應用 Download PDF

Info

Publication number
TWI847445B
TWI847445B TW111149413A TW111149413A TWI847445B TW I847445 B TWI847445 B TW I847445B TW 111149413 A TW111149413 A TW 111149413A TW 111149413 A TW111149413 A TW 111149413A TW I847445 B TWI847445 B TW I847445B
Authority
TW
Taiwan
Prior art keywords
alkyl
optionally substituted
group
compound
substituted
Prior art date
Application number
TW111149413A
Other languages
English (en)
Chinese (zh)
Other versions
TW202333713A (zh
Inventor
陳旭星
陳豔紅
Original Assignee
大陸商中山優理生物醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商中山優理生物醫藥有限公司 filed Critical 大陸商中山優理生物醫藥有限公司
Publication of TW202333713A publication Critical patent/TW202333713A/zh
Application granted granted Critical
Publication of TWI847445B publication Critical patent/TWI847445B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111149413A 2021-12-23 2022-12-22 一種噠嗪類化合物、其藥物組合物及應用 TWI847445B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111592392 2021-12-23
CN202111592392.1 2021-12-23
CN202210622049.5A CN116332960A (zh) 2021-12-23 2022-06-01 一种哒嗪类化合物、其药物组合物及应用
CN202210622049.5 2022-06-01

Publications (2)

Publication Number Publication Date
TW202333713A TW202333713A (zh) 2023-09-01
TWI847445B true TWI847445B (zh) 2024-07-01

Family

ID=86890368

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149413A TWI847445B (zh) 2021-12-23 2022-12-22 一種噠嗪類化合物、其藥物組合物及應用

Country Status (3)

Country Link
CN (2) CN116332960A (fr)
TW (1) TWI847445B (fr)
WO (1) WO2023116763A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025034849A1 (fr) * 2023-08-08 2025-02-13 Theras, Inc. Pyridazines fusionnées pour le traitement du cancer et autres indications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127429A1 (fr) * 2019-12-20 2021-06-24 Mirati Therapeutics, Inc. Inhibiteurs de sos1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2587509T3 (es) * 2009-09-18 2016-10-25 Zhanggui Wu Derivados de tieno[2,3-d]piridazina y uso terapéutico de los mismos para la inhibición de proteína cinasa
EP3558955B1 (fr) * 2016-12-22 2021-08-11 Amgen Inc. Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
US20230024438A1 (en) * 2019-12-04 2023-01-26 Arcus Biosciences, Inc. Inhibitors of hif-2alpha
CN114516883A (zh) * 2020-11-20 2022-05-20 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、其药物组合物及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127429A1 (fr) * 2019-12-20 2021-06-24 Mirati Therapeutics, Inc. Inhibiteurs de sos1

Also Published As

Publication number Publication date
WO2023116763A1 (fr) 2023-06-29
CN116332960A (zh) 2023-06-27
TW202333713A (zh) 2023-09-01
CN118434746A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN112300194B (zh) 一类稠环吡啶酮类化合物、制备方法和用途
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
WO2021027911A1 (fr) Nouvel inhibiteur de k-ras g12c spirocyclique
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN113527299B (zh) 一类含氮稠环类化合物、制备方法和用途
CN114685502A (zh) 作为kras-g12c抑制剂的螺环类化合物
CN112920180A (zh) 谷氨酰胺酶抑制剂
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
TWI810550B (zh) 3-氮雜二環烷基衍生物及包含其之醫藥組成物
WO2023143147A1 (fr) Composés de pyridazopyridone, composition pharmaceutique de ceux-ci et leur utilisation
WO2022253101A1 (fr) Composé pyridazinone utilisé comme inhibiteur de parp7
CN118574829A (zh) 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
TWI847445B (zh) 一種噠嗪類化合物、其藥物組合物及應用
CN105732643A (zh) 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
CN111039947A (zh) 一类蛋白受体激酶抑制剂的制备和应用
WO2022105636A1 (fr) Composé spiro, composition pharmaceutique le contenant et son utilisation
WO2024255863A1 (fr) Composé aminopyridine, son procédé de préparation, composition pharmaceutique le comprenant et son utilisation
TWI880239B (zh) 一種噠嗪類化合物、其藥物組合物及應用
WO2023046030A1 (fr) Inhibiteur à petite molécule egfr, composition pharmaceutique le contenant et son utilisation
CN116768870A (zh) 具有苄氧基芳基醚结构的化合物及其制备方法和用途
WO2022089296A1 (fr) Composé de thiénopyrimidine, composition pharmaceutique le comprenant et son utilisation
CN116554166A (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
WO2025050846A1 (fr) Composé, composition pharmaceutique le comprenant et son utilisation